Define Your DSAs with Greater Confidence
LABScreen™ Single Antigen ExPlex offers the most expansive HLA Antibody test in a Single Well.
Don't Wonder. Know
Testing for autoantibodies has never been more important as recent studies suggest a potential, long-term detrimental impact. The LABScreen Autoantibody assays allow you to characterize and monitor a broad range of autoantibody targets in human sera.
NGS Based Genotyping with Fast Turnaround From the Leader in HLA
AllType is a complete NGS solution that gives you the power to perform first pass, high-resolution genotyping within 3 days. As the leader in HLA for over 30 years, we provide excellent training workshops and unmatched customer support.
Celebrating a New Center of Excellence in Transplantation
On Aug. 7, we celebrated the grand opening of our new site in West Hills, Los Angeles! This state-of-the art facility provides our team with expanded labs to develop innovative solutions for transplant patients...
Upgrade to HLA Fusion™ Software 4.4 or HLA Fusion Research Software 6.3
These software updates offer new functionality, feature enhancements, and correct known minor issues.
SureTyper™ Blood is Now Available
SureTyper Blood is now available to analyze LinkSēq™ RBC, ABO and HPA kits. Customers can run SureTyper 5.0, SureTyper 6.1 and SureTyper Blood simultaneously on their computers...
What's New in SureTyper 6.1
SureTyper 6.1 contains an enhanced Tray Viewer and Well Viewer interface that allows users to visualize the reactivity of our new multi-targeted assays! Whether one target is positive, both targets are positive, or the assay is negative, the updated Tray Viewer and Well Viewer in SureTyper 6.1 provides the user with visibility to the reactivity of this enhanced assay design.
Natera Announces Agreement with One Lambda to Co-Distribute Its Kidney Transplant Rejection Test
SAN CARLOS, Calif., Feb. 1, 2019 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of cell-free DNA, today announced a partnership with Thermo Fisher Scientific's One Lambda brand...
Thermo Fisher Scientific's One Lambda Brand Signs Exclusive Licensing Agreement with Transcriptome Sciences Inc. for access to Molecular Microscope Diagnostic System
CANOGA PARK, Calif., May 16, 2017 (PRNewswire) -- One Lambda, a Thermo Fisher Scientific brand, announced today that it has signed an exclusive licensing agreement with Transcriptome Sciences Inc. (TSI) of Edmonton, Canada for its new microarray biopsy service, the Molecular Microscope™ Diagnostic System (MMDx).
One Lambda Announces the Availability of its New RUO NXType Kit, a Complete Solution for HLA Typing by NGS
CANOGA PARK, Calif.--(BUSINESS WIRE)--One Lambda, Inc., part of Thermo Fisher Scientific and leading producer of research and in vitro diagnostic products for the HLA transplant community, today launched its RUO NXType™ Kit, a research use only (RUO) solution for human leukocyte antigen (HLA) typing by next-generation sequencing (NGS). Last Updated: 2016.05.24 for trademark usage.
Thermo Fisher Scientific Completes CE-IVD Registration of its QuantStudio™ 5 Dx System for In Vitro Diagnostic Use in Europe
SAN DIEGO, July 31, 2017 (PRNewswire) -- AACC -- Thermo Fisher Scientific today announced the successful CE-IVD registration of its QuantStudio 5 Dx Real-Time PCR System for sale in European countries.
One Lambda, Inc. Announces the Availability of the Only FDA Cleared IVD Test for Detecting HNA-3
CANOGA PARK, Calif. April 7, 2015 (BUSINESS WIRE) --One Lambda, Inc., part of Thermo Fisher Scientific and leading producer of in vitro diagnostic products for the HLA transplant community, today announced the availability of the only FDA cleared and CE marked assay for detecting HNA-3, as well as HLA...
One Lambda, Inc. and GenoDive Pharma, Inc. Enter Exclusivity Agreement on Long-Range Primers for NGS
CANOGA PARK, Calif.--(BUSINESS WIRE)--One Lambda, Inc., part of Thermo Fisher Scientific, announced it has entered into an agreement with Japan-based GenoDive Pharma, Inc. for exclusive rights to their long-range primers and amplification conditions for human leukocyte antigen (HLA) locus-specific amplification. The agreement covers GenoDive’s primers and conditions for HLA A, B, C, DRB1, DRB345, DQA1, DQB1, DPA1 & DPB1 loci.
